Fatty liver in the intensive care unit

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 8, Issue 2, 2005, Pages 183-187

  Paquot, Nicolas ^a   Delwaide, Jean ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Insulin resistance; Mitochondria; Obesity; Parenteral nutrition; Steatosis

Indexed keywords

CYTOKINE; FATTY ACID; FISH OIL; GLUCOSE; LIPID; LIPID EMULSION; REACTIVE OXYGEN METABOLITE;

ACUTE PHASE RESPONSE; CALORIC INTAKE; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FATTY LIVER; GENETIC SUSCEPTIBILITY; HUMAN; INTENSIVE CARE UNIT; LIPID PEROXIDATION; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PARENTERAL NUTRITION; REVIEW; TOTAL PARENTERAL NUTRITION;

EID: 14244264497     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200503000-00013     Document Type: Review

References (42)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37:1202-1219. A critical analysis of the latest developments concerning the pathogenesis, diagnosis and treatment of NASH.
2. Pessayre D, Mansouri A, Fromenty B. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002; 282:G193-G199.
3. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40:185-194.
4. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40:46-54. This paper outlines the important role of cytokines in the pathogenesis of NASH.
5. Araya J, Rodrigo R, Videla LA, et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004; 106:635-643.
6. den Boer M, Voshol PJ, Kuipers F, et al. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 2004; 24:644-649.
7. Leclercq IA. Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis? Clin Sci (Lond) 2004; 106:235-237.
8. Videla LA, Rodrigo R, Orellana, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004; 106:261-268.
9. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004; 24:99-106.
10. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39:179-187.
11. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104:517-529.
12. Olefsky JM, Nolan JJ. Insulin resistance and non-insulin-dependent diabetes mellitus: cellular and molecular mechanisms. Am J Clin Nutr 1995; 61:980S-986S.
13. Chitturi S, Abeygunasekera S, Farrel GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with insulin resistance. Hepatology 2002; 35:373-379.
14. Medina J, Fernadez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004; 27:2057-2066. An excellent and comprehensive review of the pathogenesis and treatment of NASH. The authors provide a good, clinically oriented overview.
15. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293:1673-1677.
16. Uysal KT, Wiesbrock S, Marino M, Hotamisligil G. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389:610-614.
17. Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34:1158-1163.
18. Pessayre D, Fromenty B, Mansouri A. Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol 2004; 16:1095-1105.
19. Fromenty B, Robin MA, Igoudjil A, et al. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004; 30:121-138. A very stimulating review of the role of mitochondrial dysfunction in the pathophysiology of NASH. It describes biochemical mechanisms involved in steatohepatitis liver lesions and outlines the importance of genetic susceptibility.
20. Mori S, Yamasaki T, Sakaida I, et al. Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol 2004; 39:391-396.
21. Musso G, Cambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37:909-916.
22. Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38:413-419.
23. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in hepato-hepatitis. Semin Liver Dis 2001; 21:57-69.
24. Dixon JB, Bhatahal PS, Hugues NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39:1647-1654. Interesting study showing major improvement in the histological features of liver disease after surgically induced weight loss.
25. Urso R, Visco-Comandini U. Metformin in non-alcoholic steatohepatitis [letter]. Lancet 2002; 359:355-356.
26. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with PPAR-γ ligand rosiglitazone. Hepatology 2003; 38:1008-1017.
27. Harrison SA, Ramrakhiari S, Brunt E, et al. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003; 98:926-930.
28. Feher J, Lengyel G. A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J Int Med Res 2003; 31:537-551.
29. Jeejeebhoy KN, Anderson GH, Nakhooda AF, et al. Metabolic studies in total parenteral nutrition with lipid in man. Comparison with glucose. J Clin Invest 1976; 57:125-136.
30. Sheldon GF, Peterson SR, Sanders R. Hepatic dysfunction during hyper-alimentation. Arch Surg 1978; 113:504-508.
31. Baker AL, Rosenberg IH. Complications of total parenteral nutrition. Am J Med 1987; 82:489-497.
32. Driscoll DF, Blackburn GL. Total parenteral nutrition in 1990. Drugs 1990; 40:346-363.
33. Buchman A. Total parenteral nutrition-associated liver disease. J Parenter Enteral Nutr 2002; 26:S43-S48.
34. Jolliet P, Leverve X, Pichard C. Acute steatosis complicating massive insulin overdose and excessive glucose administration. Intensive Care Med 2001; 27:313-316.
35. Krawinkel MB. Parenteral nutrition-associated cholestasis - what do we know, what can we do? Eur J Pediatr Surg 2004; 14:230-234.
36. Simoens Ch, Deckelbaum RJ, Carpentier YA. Metabolism of defined structured triglyceride particles compared to mixtures of medium and long chain triglycerides intravenously infused in dogs. Clin Nutr 2004; 23: 665-672.
37. Rubin M, Moser A, Vaserberg N, et al. Structured triacylglycerol emulsion, containing both medium- and long-chain fatty acids, in long-term home parenteral nutrition: a double-blind randomized cross-over study. Nutrition 2000; 16:95-100.
38. Nijveldt RJ, Tan AM, Prins HA, et al. Use of a mixture of medium-chain triglycerides and longchain triglycerides versus long-chain triglycerides in critically ill surgical patients: a randomized prospective double-blind study. Clin Nutr 1998; 17:23-29.
39. Heller AR, Rossel T, Gottschlich B, et al. Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. Int J Cancer 2004; 111:611-616.
40. Chen WJ, Yeh SL. Effects of fish oil in parenteral nutrition. Nutrition 2003; 19:275-279.
41. Barret JP, Jeschke MG, Herndon DN. Fatty infiltration of the liver in severely burned pediatric patients: autopsy findings and clinical implications. J Trauma 2001; 51:736-739.
42. Jeschke MG, Barrow RE, Herndon DN. Extended hypermetabolic response of the liver in severely burned pediatric patients. Arch Surg 2004; 139:641-647.